MX2018002099A - Compuestos y métodos para la administración transmembranal de moléculas. - Google Patents
Compuestos y métodos para la administración transmembranal de moléculas.Info
- Publication number
- MX2018002099A MX2018002099A MX2018002099A MX2018002099A MX2018002099A MX 2018002099 A MX2018002099 A MX 2018002099A MX 2018002099 A MX2018002099 A MX 2018002099A MX 2018002099 A MX2018002099 A MX 2018002099A MX 2018002099 A MX2018002099 A MX 2018002099A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- delivery
- trans
- molecules
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporciona un novedoso sistema de administración fármacos, y especialmente de macromoléculas como proteínas u oligonucleótidos a través de las membranas biológicas, y específicamente la administración de ARNip. El sistema de administración comprende la conjugación del fármaco macromolecular a una porción que permite el paso eficaz a través de las membranas. Por tanto, se proporcionan novedosos compuestos y composiciones farmacéuticas, con la utilización de dicho sistema de administración. En un aspecto de la invención, los compuestos pueden utilizarse en la práctica médica, por ejemplo, en la administración de ARNip u oligonucleótidos antisentido a través de las membranas biológicas para el tratamiento de trastornos médicos.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/830,799 US9687556B2 (en) | 2014-03-28 | 2015-08-20 | Compounds and methods for trans-membrane delivery of molecules |
US14/872,179 US9889202B2 (en) | 2014-03-28 | 2015-10-01 | Compounds and methods for trans-membrane delivery of molecules |
US14/985,526 US20160120996A1 (en) | 2014-03-28 | 2015-12-31 | Compounds and methods for trans-membrane delivery of molecules |
US15/057,813 US20170080095A1 (en) | 2014-03-28 | 2016-03-01 | Compounds and methods for trans-membrane delivery of molecules |
US15/164,344 US20170037401A1 (en) | 2014-03-28 | 2016-05-25 | Compounds and methods for trans-membrane delivery of molecules |
US15/222,559 US9993563B2 (en) | 2014-03-28 | 2016-07-28 | Compounds and methods for trans-membrane delivery of molecules |
PCT/IL2016/050893 WO2017029664A1 (en) | 2015-08-20 | 2016-08-17 | Compounds and methods for trans-membrane delivery of molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018002099A true MX2018002099A (es) | 2018-09-18 |
Family
ID=58051108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002099A MX2018002099A (es) | 2015-08-20 | 2016-08-17 | Compuestos y métodos para la administración transmembranal de moléculas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9993563B2 (es) |
EP (1) | EP3337515B1 (es) |
JP (1) | JP7366539B2 (es) |
KR (1) | KR20180042350A (es) |
CN (1) | CN108135924B (es) |
AU (1) | AU2016308066B2 (es) |
BR (1) | BR112018003316A2 (es) |
CA (1) | CA2995663A1 (es) |
IL (1) | IL257507B (es) |
MX (1) | MX2018002099A (es) |
RU (1) | RU2756569C1 (es) |
WO (1) | WO2017029664A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
IL294014B1 (en) | 2015-10-23 | 2024-03-01 | Harvard College | Nucleobase editors and their uses |
EP3426349A4 (en) | 2016-03-09 | 2020-01-01 | Ionis Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
CA3049640A1 (en) | 2017-01-09 | 2018-07-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
KR102206676B1 (ko) * | 2017-06-14 | 2021-01-26 | 한국과학기술원 | 비바이러스성 유전자편집 crispr 나노복합체 및 이의 제조방법 |
US10195286B2 (en) * | 2017-07-04 | 2019-02-05 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11236334B2 (en) | 2017-08-22 | 2022-02-01 | National University Corporation Nagoya University | Modified polynucleotide |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CA3087294A1 (en) * | 2018-01-01 | 2019-07-04 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
JP2020105498A (ja) * | 2018-12-26 | 2020-07-09 | 群栄化学工業株式会社 | ポリイミン、ポリイミンイミド、ワニス、フィルム及びその製造方法、並びに積層体及びその製造方法 |
EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN110059427B (zh) * | 2019-04-24 | 2023-04-07 | 杭州电子科技大学 | 自驱动微纳米马达输运系统、运输方法及模拟方法 |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0935415B1 (en) | 1996-05-01 | 2006-11-22 | Imarx Pharmaceutical Corp. | In vitro methods for delivering nucleic acids into a cell |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
WO1998050041A1 (en) | 1997-05-06 | 1998-11-12 | Imarx Pharmaceutical Corp. | Novel prodrugs comprising fluorinated amphiphiles |
FR2846969A1 (fr) | 2002-11-08 | 2004-05-14 | Salles Jean Pierre | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
SE527131C2 (sv) | 2004-02-13 | 2005-12-27 | Innoventus Project Ab | Steroider för cancerbehandling |
ES2383901T5 (es) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
CA2663601C (en) | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
ES2404131T3 (es) | 2008-05-13 | 2013-05-24 | University Of Washington | Copolímeros de dibloques y sus complejos con polinucleótidos para el suministro en células |
WO2009155335A2 (en) | 2008-06-19 | 2009-12-23 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization |
CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
CA2944141C (en) * | 2014-03-28 | 2023-03-28 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
-
2016
- 2016-07-28 US US15/222,559 patent/US9993563B2/en active Active
- 2016-08-17 JP JP2018508650A patent/JP7366539B2/ja active Active
- 2016-08-17 WO PCT/IL2016/050893 patent/WO2017029664A1/en active Application Filing
- 2016-08-17 BR BR112018003316A patent/BR112018003316A2/pt not_active Application Discontinuation
- 2016-08-17 KR KR1020187007848A patent/KR20180042350A/ko unknown
- 2016-08-17 CN CN201680055005.1A patent/CN108135924B/zh active Active
- 2016-08-17 EP EP16836749.8A patent/EP3337515B1/en active Active
- 2016-08-17 RU RU2018109110A patent/RU2756569C1/ru active
- 2016-08-17 AU AU2016308066A patent/AU2016308066B2/en active Active
- 2016-08-17 MX MX2018002099A patent/MX2018002099A/es unknown
- 2016-08-17 CA CA2995663A patent/CA2995663A1/en not_active Abandoned
-
2018
- 2018-02-13 IL IL257507A patent/IL257507B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20180042350A (ko) | 2018-04-25 |
IL257507B (en) | 2021-01-31 |
JP2018523680A (ja) | 2018-08-23 |
AU2016308066A1 (en) | 2018-03-15 |
CA2995663A1 (en) | 2017-02-23 |
JP7366539B2 (ja) | 2023-10-23 |
BR112018003316A2 (pt) | 2018-09-18 |
WO2017029664A1 (en) | 2017-02-23 |
EP3337515A1 (en) | 2018-06-27 |
CN108135924A (zh) | 2018-06-08 |
US9993563B2 (en) | 2018-06-12 |
IL257507A (en) | 2018-04-30 |
RU2756569C1 (ru) | 2021-10-01 |
EP3337515B1 (en) | 2024-03-13 |
US20170100486A1 (en) | 2017-04-13 |
CN108135924B (zh) | 2021-07-13 |
AU2016308066B2 (en) | 2022-06-16 |
EP3337515A4 (en) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018002099A (es) | Compuestos y métodos para la administración transmembranal de moléculas. | |
MX2016012716A (es) | Compuestos y metodos para suministro trans-membrana de moleculas. | |
EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
MA37206B1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
CY1118081T1 (el) | Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo | |
WO2018071741A8 (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
MX2016016992A (es) | Aptameros especificos de tlr-4 y usos de los mismos. | |
EA201991661A1 (ru) | Соединения и способы трансмембранной доставки молекул |